Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: The comparison of Efficacy between COroflex PLEASe ANd Taxus stent (ECO-PLEASANT) randomized controlled trial

Title
Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: The comparison of Efficacy between COroflex PLEASe ANd Taxus stent (ECO-PLEASANT) randomized controlled trial
Author(s)
박종선서재빈[서재빈]강시혁[강시혁]허승호[허승호]박경우[박경우]연태진[연태진]양한모[양한모]이해영[이해영]강현재[강현재]구본권[구본권]배장호[배장호]김상욱[김상욱]문건웅[문건웅]최재웅[최재웅]이상곤[이상곤]정우영[정우영]김수중[김수중]김두일[김두일]김병옥[김병옥]현민수[현민수]박금수[박금수]차태준[차태준]유철웅[유철웅]전의경[전의경]김효수[김효수]
Keywords
CORONARY-ARTERY LESIONS; MUSCLE-CELL PROLIFERATION; ANGIOGRAPHIC FOLLOW-UP; CLINICAL-PRACTICE; DIABETIC-PATIENTS; STRUT THICKNESS; SLOW-RELEASE; IN-VITRO; RESTENOSIS; REVASCULARIZATION
Issue Date
201305
Publisher
MOSBY-ELSEVIER
Citation
AMERICAN HEART JOURNAL, v.165, no.5, pp.733 - 743
Abstract
Aims Paclitaxel-eluting stents (PESs) have been shown to inhibit neointimal hyperplasia after percutaneous coronary intervention. Coroflex Please (B Braun, Melsungen, Germany) is a newly developed PES. We compared the clinical and angiographic efficacy of Coroflex Please with Taxus Liberte (Boston Scientific, Natick, MA) in a real-world practice. Methods and Results We performed a prospective, open-label, randomized, controlled study that enrolled 945 patients undergoing percutaneous coronary interventions in 18 centers in Korea. The primary end point was clinically driven target vessel revascularization at 9 months. The baseline characteristics were mostly similar and comparable between 2 groups. At 9 months, the incidence of clinically driven target vessel revascularization was 14.6% for Coroflex and 6.4% for Taxus, which was significantly different (hazard ratio 2.43, 95% CI 1.50-3.94, noninferiority P value = 1.000). This is well corroborated by the difference of in-stent late loss between 2 stents (0.71 +/- 0.64 mm vs 0.52 +/- 0.50 mm, P < .001) by 9-month follow-up angiography (n = 415 vs 215). Among secondary clinical end points, stent thrombosis (definite and probable) for 1 year was 2.2% in Coroflex and 1.3% in Taxus (P = .317). Also, myocardial infarction for 9 months was higher in Coroflex group than that in Taxus (4.9% vs 1.6%, P = .012), which was partly contributed by the higher incidence of periprocedural myocardial infarction in Coroflex arm (2.2% vs 0.3%, P = .028). Conclusions Coroflex Please was inferior to Taxus Liberte with regard to clinical and angiographic efficacy. (Am Heart J 2013;165:733-43.)
URI
http://hdl.handle.net/YU.REPOSITORY/25864http://dx.doi.org/10.1016/j.ahj.2013.02.009
ISSN
0002-8703
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE